-
-
-
-
-
-
-
United Community Banks completes merger with Peach State Bancshares
-
-
-
-
-
-
-
UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
-
-
-
-
-
-
-
Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB
-
-
-
-
-
-
-
UCB to acquire Neurona Therapeutics for up to $1.15 billion
-
-
-
-
-
-
-
BIMZELX®▼(bimekizumab) superior to SKYRIZI® (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
-
-
-
-
-
-
-
U.S. FDA approves KYGEVVI® (doxecitine and doxribtimine), the first and only treatment for adults and children living with thymidine kinase 2 deficiency (TK2d)
-
-
-
-
-
-
-
United Community Banks, Inc. Reports Third Quarter Earnings
-
1,187,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

